The survival advantage of women over men with cutaneous melanoma and the reports of accelerated progression of melanoma during pregnancy have led to studies of the effect of hormones and hormone receptors on the development and progression of melanoma. However, the results are inconclusive. We therefore evaluated the expression of estrogen receptor a, estrogen receptor b, and androgen receptor in melanomas of stage-and agematched pregnant women, nonpregnant women, and men by immunohistochemical analysis of formalin-fixed, paraffin-embedded archival tissues. In addition, we also assessed the mitotic rate using the antiphosphohistone H3 antibody by immunohistochemistry. Our data showed a trend of more frequent expression of estrogen receptor b in the melanomas of pregnant patients than in the melanomas of male patients, without a significant difference observed between pregnant and nonpregnant women. However, no association between the expression of estrogen receptor b and survival was observed. The small cohort may have limited the statistical power of the study, and large-scale studies are needed to elucidate the potential role of estrogen receptor b as a prognostic marker of melanoma.
INTRODUCTION
Cutaneous melanoma, one of the most frequently encountered malignancies in pregnant women, accounts for 25% of all cancers diagnosed during pregnancy 1 and is diagnosed up to 1 in 1000 gestations. 2 The incidence of melanoma during pregnancy is expected to rise due to the increased incidence of melanoma in the general population and the relatively high incidence of melanoma in women of childbearing age ( Fig. 1 ; Surveillance Epidemiology and End Results data). Although most agree that women have a significant survival advantage over men in cutaneous melanoma, 3 the effects of pregnancy, sex hormones, and hormone receptors on the survival of melanoma patients are still controversial. 4, 5 de Giorgi et al 6 showed that melanoma expressed detectable estrogen receptor a (ERa) and estrogen receptor b (ERb) mRNA by reverse transcriptase-polymerase chain reaction. They also demonstrated that ERb protein was expressed in melanomas using immunohistochemical analysis. However, no study has been performed to compare the immunohistochemical expressions of estrogen and androgen receptors in the melanomas of pregnant women, nonpregnant women, and men. Therefore, we conducted this retrospective study to assess the expression of hormone receptors in the melanomas of stage-and age-matched pregnant women, nonpregnant women, and men. We hypothesized that the melanomas of pregnant women have a higher prevalence of expression of hormone receptors than those of nonpregnant women and men and we assessed the possible role of hormone receptor expression as a prognostic marker. In addition, we evaluated the tumor mitotic rate in stages III and IV melanomas by immunohistochemical analysis using antiphosphohistone H3 (pHH3) antibody and assessed its association with prognosis.
MATERIALS AND METHODS
This study was approved with waived informed consent by the Institutional Review Board of The University of Texas MD Anderson Cancer Center. The electronic medical records of the patients included in the study were reviewed to record relevant data (age, race, pregnancy status, gestational age, tumor site, tumor type, the Breslow thickness of tumor, ulceration, primary tumor vs metastasis, disease stage, metastatic site, treatment received, date of initial diagnosis, date of disease progression, date of last follow-up, and date of death). primary melanoma was from a noncutaneous site. The remaining 18 patients were included in the study group.
The Nonpregnant Women and Men Control Patients
Using the search criteria "metastatic melanoma, age range 20-45 years, from January 1996 to December 2011," in the database of the Department of Pathology at MDACC, we identified 18 women who were not pregnant at the time of or within 1 year of diagnosis and 18 men as the control patients. These nonpregnant women and men were stageand age matched to the pregnant study patients. For the patients with stages III or IV disease, the first order of match was the clinical stage. The metastatic site in patients with stage IV disease was also matched. The second order of match was the Breslow thickness of the tumor by the pT stage of the seventh edition of the American Joint Committee on Cancer staging manual. Additional database searches were performed to identify cases that matched the patients who had stage I disease in which the Breslow thickness of the tumor was matched as close to that of the study patients as possible.
Immunohistochemistry
The appropriate formalin-fixed, paraffin-embedded tissue blocks were obtained after reviewing the hematoxylin and eosin-stained slides. The immunohistochemical reaction was performed using a BOND MAX automated system (Leica Microsystems, Buffalo Grove, IL) according to the manufacturer's protocol. Briefly, 4-mm of tissue sections were dewaxed, washed, and incubated with antibodies against ERa (clone 6F11; Novocastra, Newcastle Upon Tyne, United Kingdom; dilution 1:35), ERb (clone EMR02; Leica Microsystems, Buffalo Grove, IL; dilution 1:100), androgen receptor (clone AR441; Dako, Carpinteria, CA; dilution 1:30), and pHH3 (Upstate Millipore, Temecula, CA; dilution 1:400) at room temperature for 15 minutes. The slides then were treated with Epitope Retrieval (Leica Microsystems) in citrate buffer for 5 minutes after washing. Endogenous peroxidase activity was blocked by Peroxide Block (Leica Microsystems) for 5 minutes. After washing, the sections were incubated with Post Primary immunoglobulin G linker reagent (polymer enhancer; Leica Microsystems) for 8 minutes and then incubated with Poly-Horseradish Peroxidase immunoglobulin G polymer (Leica Microsystems) for 8 minutes after washing. The immunoreaction was visualized using 3,3 0 -diaminobenzidine and hematoxylin counterstaining. Appropriate positive and negative controls for each antibody were performed simultaneously with the samples.
Hormone Receptor Expression and Mitotic Rate
We defined the positive expression of hormone receptors as 10% or more of the tumor cells having positive nuclear staining (Fig. 2) . The expression was recorded as both binary and continuous (percent positive) variables. The mitotic rate was defined as the number of pHH3-positive tumor cell nuclei per square millimeter, corresponding to 4.5 consecutive fields at ·40 magnification on an Olympus BX41 microscope. The consecutive fields were determined by scanning the slides to find the "hotspot" area with the highest numbers of pHH3positive tumor cell nuclei as the first field to start the counting.
Evaluation of the Immunohistochemical Expression
The immunohistochemically stained slides were examined by 2 pathologists (J.H.Z. and V.G.P.) using the definition above for the expression of hormone receptors. The pHH3 counts were performed together by the 2 pathologists with a double-headed microscope and the results were scored as a consensus between the 2 pathologists.
Follow-Up and Survival
The follow-up time was calculated from the date each specimen was collected at MDACC until the patient's death or the last follow-up at MDACC through the end of July 2012. The survival time was calculated from the date each specimen was collected at MDACC until the patient's death or the last follow-up at MDACC through the end of July 2012 using the Kaplan-Meier method taking into account censoring.
Statistical Methods
The McNemar exact test was used to assess the differences in hormone receptor expression between pregnant patients and nonpregnant control patients and male control patients. The Fisher exact and Wilcoxon rank sum tests were used to assess the association of hormone receptor expression with the Breslow thickness of tumor, primary tumor site, primary tumor or metastasis, and disease stage. The Kaplan-Meier survival curves were used to estimate survival, and the log-rank test was used to assess the differences in survival between the pregnant group and the 2 control groups. Fixed effects Cox regression was performed to assess the expression of ERb on overall survival taking into account matching. The Kruskal-Wallis test was used to evaluate the differences in follow-up and survival times among the 3 patient groups. The Spearman rank-order correlation was used to assess the association of pHH3 with the Breslow thickness and ERb expression. A p value ,0.05 was considered statistically significant. All statistical analyses were performed using SAS 9.2 for Windows (SAS Institute Inc, Cary, NC). 
RESULTS

Patient and Tumor Characteristics
Hormone Receptor Expression
The results of the immunohistochemical analyses are summarized in Table 2 . Only 2 cases expressed ERa. One was from a pregnant patient, and the other was from a male control patient. Both patients had acral lentiginous-type melanoma of the toe.
Of 22 cases that expressed ERb, 10 (56%) were from pregnant patients, 7 (39%) were from nonpregnant female control patients, and 5 (29%) were from male control patients. The percentage of ERb-positive cells ranged from 30% to more than 90%. A trend of more frequent ERb expression was observed in pregnant patients than in male patients (P = 0.07). No significant difference of ERb expression was observed between pregnant and nonpregnant female patients (P = 0.54). The ERb expression was not associated with the Breslow thickness of tumor (P = 0.51), primary tumor site (P = 0.94), primary tumor or metastasis (P = 0.40), or disease stage at diagnosis (P = 0.79). The ERb expression did not correlate with the survival time from the dates the specimens were collected (hazard ratio, 1.215; 95% confidence interval for hazard ratio, 0.472-3.131; P = 0.69).
None of the cases expressed androgen receptor.
Mitotic Rate by pHH3
The mitotic rate by pHH3 labeling ranged from 1 to 42/mm 2 (median 9.5/mm 2 ) for the pregnant patients, 0 to 18/mm 2 (median 11/mm 2 ) for the nonpregnant female control patients, and 1 to 42/mm 2 (median 10/mm 2 ) for the male control patients. The pHH3 count was significantly higher in stage IV tumors than in stages I or III tumors (P = 0.0001) and was I  3  3  3  II  0  0  0  III  3  3  3  IV  12  12  12 significantly higher in metastatic tumors than in primary tumors (P = 0.0003). However, the pHH3 count was not associated with the survival time (P = 0.09). The pHH3 count was not significantly associated with the Breslow thickness of tumor (P = 0.09) or primary tumor site (P = 0.34). No association between pHH3 count and ERb expression was observed (P = 0.53).
Follow-Up
From the dates the specimens were collected at MDACC, the median follow-up times for the pregnant patients, nonpregnant female control patients, and male control patients were 15.8 months (range, 3.8-96.5 months), 28.5 months (range, 3.7-126 months), and 25.8 months (range, 0.03-99.1 months), respectively ( Table 2 ). The differences in the follow-up times among the 3 groups were not statistically significant (P = 0.46).
Survival Time
From the dates the specimens were collected at MDACC, the median survival time for the pregnant patients, nonpregnant female control patients, and male control patients were 37.6 months (range, 3.8-96.5 months), 28.8 months (range, 3.7-126 months), and 27.7 months (range, 0.03-99.1 months), respectively. The difference in survival time among the 3 groups was not statistically significant (P = 0.87). The survival time subset only to the stage IV patients for the pregnant patients, the nonpregnant female control patients, and the male control patients were 13.6 months (range, 3.9-96.3 months), 22.5 months (range, 3.7-97.4 months), and 11 months (range, 0.03-74.2 months), respectively ( Table 2) . The difference in the survival times among the 3 groups was not statistically significant (P = 0.76) ( Fig. 3 ).
Treatment Received
All the patients with primary tumors in both the study and the control groups underwent wide local excision and sentinel lymph node dissection after biopsy confirmation of melanoma. When the sentinel lymph node was positive for melanoma, regional lymphadenectomy was performed and systemic staging procedures were carried out. Patients with stage I disease were monitored without adjuvant therapy. A total of 5 patients with stage III disease (2 pregnant patients, 2 male control patients, and 1 female control patient) refused adjuvant therapy. Two patients with stage IV disease (both in the male control group) refused adjuvant therapy. The remaining patients received at least 1 type of adjuvant therapy, including interferon, biochemotherapy, chemotherapy alone, chemotherapy plus radiation therapy, bioimmunotherapy, anti-CTLA4, granulocyte macrophage-colony-stimulating factor, or tumor-infiltrating lymphocytes and interleukin-2.
One patient received Proto-oncogene B-Raf (BRAF) inhibitor, and another patient received BRAF plus Mitogenactivated or extracellular signal-regulated protein kinase (MEK) inhibitors.
DISCUSSION
Although our study did not reveal a statistically significant difference in ERb expression, a trend in our findings indicated that ERb was more frequently expressed in the melanomas of pregnant women than in men, but no difference in ERb expression was found between pregnant and nonpregnant women. These findings warrant further study. To our knowledge, this is the first study to evaluate hormone receptor expression in the melanomas of stage- Survival time subset to stage IV disease (mo), median/range and age-matched patients of pregnant women, nonpregnant women, and men. Both ERa and ERb proteins are expressed in the normal skin. 7 However, previous studies showed that ERb protein is frequently expressed in cutaneous melanoma, whereas ERa protein is rarely expressed. 7, 8 Our findings confirm this observation. Studies 9-11 of estrogen-sensitive cancers such as breast and ovarian cancers showed that loss or decreasing levels of ERb or increased ERa to ERb ratio may be involved in carcinogenesis, thereby suggesting that ERb has a tumorsuppressive function. Studies of estrogen receptors in prostate and colon cancers yielded similar results. [12] [13] [14] [15] Omoto et al 16 performed a survival analysis of patients with invasive breast cancer and found that 5-year disease free survival was longer in patients with ERb-positive tumors than in those with ERbnegative tumors. We speculate that ERb might explain the generally favorable prognosis of melanoma in women, although we could not statistically confirm this possibility based on our data. This could potentially be due to the small cohort, which probably limited the statistical power of the study. Fuqua et al 17 studied ERb expression by immunohistochemical analysis in 242 breast cancer patients and found that ERb expression was not associated with clinical and biologic parameters but correlated with aneuploidy, thereby suggesting that ERb expression could be an independent prognostic marker. Likewise, we did not find any association of ERb expression with clinical or pathologic parameters such as the Breslow thickness, mitotic rate as assessed by pHH3 immunohistochemical analysis, tumor site, and primary or metastatic tumors. Schmidt et al 8 evaluated the immunohistochemical expression of ERa and ERb in various cutaneous melanocytic lesions and found that ERb expression was most prominent in lesions close to the epidermis, such as severely dysplastic nevus or melanoma in situ and that the expression diminished in deeper and thicker lesions, thereby suggesting that ERb may serve as a prognostic marker in melanoma. Studies by de Giorgi et al 6 on ERb in cutaneous melanoma revealed similar findings. We were not able to confirm these findings probably because of the relative predominance of metastatic tumors in our study.
Reports of the development and accelerated progression of melanoma in pregnancy have led to several retrospective case-control studies of the effect of pregnancy on melanoma survival. Some reported poorer outcome when melanoma developed during pregnancy, [18] [19] [20] whereas others showed that pregnancy did not significantly affect survival in patients with stages I or II disease. [21] [22] [23] [24] [25] However, no such studies have included patients with stages III or IV disease. Most of our patients had stage IV disease, and our data did not show any significant difference in survival between the pregnant patients and the nonpregnant female and male control patients.
Little is known on the expression of androgen receptor in human melanoma. Brinton et al 26 assessed cancer risk among infertile women with androgen excess disorders and found that the standardized incidence ratio was statistically significant for breast cancer, uterine cancer, and melanoma (standardized incidence ratio, 1.96; 95% confidence interval, 1.12-3.18). Apolipoprotein D, an androgen-regulated protein, has been found in cutaneous melanoma. 27 An animal study by Hsueh et al 28 showed that androgen blockade enhanced the response to melanoma vaccine in male mice. Richardson et al 29 found that 17b estrodiol and estrone inhibited invasion and dehydroepiandrosterone enhanced invasion in melanoma cell lines. The same authors also found that the serum estrogen/androgen index was decreased in female patients with stage IV disease, although this finding was not statistically significant. We did not find any expression of androgen receptor in the specimens included in our study.
Mitotic rate has been found to be a prognostic factor in primary cutaneous melanoma. [30] [31] [32] [33] [34] The conventional method of counting the mitotic rate on slides stained with hematoxylin and eosin is time consuming and could demonstrate considerable intra-and interobserver variations. The pHH3 is produced by the phosphorylation of histone 3 during mitotic chromatin condensation in the late G2 and M phases of the cell cycle. The pHH3 immunohistochemical staining has been shown to be both sensitive and highly specific for the detection of mitosis because it does not label apoptotic cells. [35] [36] [37] Therefore, assessing pHH3 nuclear staining of the tumor cells is more efficient and reliable than the conventional method. 38, 39 Furthermore, pHH3 staining has been reported to be very useful in facilitating objective grading in meningiomas 40 and astrocytomas, 41 in differentiating melanoma from nevi 42 and in evaluating thin melanomas. 43 Recently, Ladstein et al 44 reported that the pHH3 count is a stronger prognostic indicator than the mitotic rate as assessed by hematoxylin and eosin staining for disease-specific survival in nodular melanomas with a Breslow thickness of 0.7-44.0 mm. Our data indicate that the pHH3 count is significantly higher in patients with stage IV disease and in metastatic tumors than in stages I or III disease or primary tumors. However, we did not discern any association of pHH3 with the survival time, which was most likely attributable to the relatively small cohort.
In summary, we observed a trend that ERb was more frequently expressed in the melanomas of pregnant women than in those of men, but not in those of nonpregnant women. The small cohort may have limited the statistical power of the study. Larg-scale studies are needed to elucidate the potential role of ERb as a prognostic marker of melanoma.
